Estrogen-induced Prolactin Research Articles

Neuroendocrine system as therapeutic target of vitex agnus castus fruit extract for premenstrual syndrome

The article regards to neuroendocrine mechanisms of development of latent hyperprolactinemia in the patients with premenstrual syndrome (PMS) and to some aspects of its impact on water-salt metabolism and ovarian cyclicity. The author has proposed the concept of interrelation between neurotransmitters and regulatory peptides in neuroendocrine control of prolactin secretion in PMS patients with a special reference to the role of hypothalamic tubero-infundibular dopaminergic system and galanin. According to this concept, hypothalamic dopamine is communicative link between stress- and estrogen-induced prolactin secretions. Given the current knowledge on the PMS pathogenesis, usage of Cyclodynon and Mastodynon which contain a special Vitex Agnus Castus fruit extract with proved dopaminergic activity for treatment of PMS accompanied by latent hyperprolactinemia is reasonable and save

Levonorgestrel Antagonism on Estrogen-induced Pituitary Tumors Is Mediated by Progesterone Receptors

Using both IN VITRO and IN VIVO approaches, we studied the antagonism exerted by the synthetic progestin levonorgestrel on estrogen-induced prolactinomas, considering that levonorgestrel shows partial androgenic properties and that androgens inhibit estrogen-induced prolactin synthesis and secretion. In the tumors, binding of estrogens to their receptors was competed neither by progesterone receptor ligands nor by androgen receptor ligands, ruling out direct inhibitory effects of these drugs on tumor development. Progestin binding was competed by the progesterone receptor agonists progesterone and levonorgestrel, by the antagonist mifepristone, and also by the androgen dihydrotestosterone, whereas the androgen receptor antagonist hydroxyflutamide was a weak competitor. In addition, both progesterone receptor and androgen receptor ligands competed for binding to androgen receptors. In primary cultures of pituitary tumors, levonorgestrel decreased prolactin secretion, an effect that was blocked by mifepristone but not by hydroxyflutamide. IN VIVO results indicated that levonorgestrel inhibition of both estrogen-induced pituitary weight increment and hyperprolactinemia was reduced by mifepristone, whereas flutamide was unable to block levonorgestrel effects. Our results suggest that even when an interaction of levonorgestrel with androgen receptors in the tumors is possible, the antagonistic effects of levonorgestrel on tumor development and functionality are mediated by progesterone receptors.

Involvement of angiotensin II, TRH and prolactin-releasing peptide in the estrogen-induced afternoon prolactin surge in female rats: studies using antisense technology

The roles of endogenous angiotensin II (AII), thyrotropin-releasing hormone (TRH) and prolactin-releasing peptide (PrRP) on the estrogen-induced prolactin (PRL) surge and the diurnal change of tuberoinfundibular dopaminergic (TIDA) neuronal activity were assessed in this study. Ovariectomized, estrogen-primed rats implanted with intracerebroventricular cannula received daily injection of antisense oligodeoxynucleotide (ODN, 10 μg/3 μl) against the mRNA of AII, TRH or PrRP for two days. Artificial cerebrospinal fluid or the sense ODN were used as the control. In the first experiment, serial blood samples (0.3 ml each) were obtained hourly from each rat through a pre-implanted intraatrial catheter from 1100 to 1700h. Half of the rats pretreated with respective antisense ODN received single injections of AII, TRH or PrRP (1 μg each, iv) at 1400h. In the second experiment, groups of rats were decapitated either at 1000 or 1500h. The hypothalamic median eminence tissue of each rat was dissected out and its DOPAC content was used as the index for TIDA neuronal activity. Plasma and serum PRL levels were determined by radioimmunoassay. Pretreatment of antisense ODN against the mRNA of either AII or TRH significantly attenuated the PRL surge; replacement injection of AII or TRH restored the surge. The effect of antisense ODN against PrRP was less significant. None of the treatments significantly affected the diurnal changes of TIDA neuronal activity. In summary, both AII and TRH may play an important role as the PRL-releasing hormone involved in the estrogen-induced afternoon PRL surge.

Influence of GnRH agonist and neural antagonists on stress-blockade of LH and prolactin surges induced by 17beta-estradiol in ovariectomized rats.

In our previous study, we demonstrated that immobilization stress blocked estrogen-induced luteinizing hormone (LH) surge possibly by inhibiting the synthesis and release of gonadotropin-releasing hormone (GnRH) at the hypothalamic level and by blocking estrogen-induced prolactin (PRL) surge by increasing the synthesis of dopamine receptor at the pituitary level in ovariectomized rats. The present study was performed to determine whether immobilization stress affects pituitary LH responsiveness to GnRH, and whether endogenous opioid peptide (EOP) and dopamine systems are involved in blocking LH and PRL surges during immobilization stress. Immobilization stress was found to inhibit basal LH release and to completely abolish LH surge. However, the intravenous application of GnRH agonist completely restored immobilization-blocked LH surge and basal LH release. Treatment with naloxone did not exert any effect on immobilization-blocked LH surge but increased basal LH release during immobilization stress. Pimozide did not affect immobilization-blocked LH surge or basal LH release. Naloxone also decreased immobilization-induced basal PRL release, but had no effect on immobilization-blocked PRL surge. Immobilization-increased basal PRL levels were augmented by pimozide treatment and immobilization-blocked PRL surge was dramatically restored by pimozide. We conclude that immobilization stress does not impair pituitary LH response to GnRH, and that the immobilization stress-induced blockage of LH surge is probably not mediated by either the opioidergic or the dopaminergic system. However, immobilization-blockade of PRL surge may be partly mediated by the dopaminergic system.

Effect of serotonin depletion by p-chlorophenylalanine on serum prolactin levels in estrogen-treated ovariectomized rats: insights concerning the serotoninergic, dopaminergic and opioid systems.

The stimulatory effect of serotonin on prolactin secretion is well documented, and the administration of an inhibitor of serotonin synthesis (p-chlorophenylalanine - pCPA) has the expected inhibitory action on prolactin release in most experimental situations. However, there is evidence that in certain physiological or experimental conditions, activation of the serotoninergic system can also determine inhibition of prolactin secretion. The aim of the present study was to investigate the ability of estrogen to modify the effect of pCPA on prolactin secretion and to evaluate the participation of opioid and/or dopaminergic systems in regulating pCPA-induced prolactin secretion in estradiol-treated rats. We observed that pCPA administration (200 mg/kg/day, s.c., 2 days) to ovariectomized (OVX) female rats treated with estradiol benzoate (300 microg/week for 2 weeks, or 50 microg/week for 4 weeks, s.c.) causes a significant increase in serum prolactin, whereas no effect is observed in intact rats or in OVX rats without treatment. Bromocriptine administration completely reversed prolactin values previously increased by estradiol and by pCPA [OVX rats + estradiol = 86.50 ng/ml (68.90-175.02), OVX + estradiol + pCPA = 211.30 ng/ml (142.03-311.00), OVX + estradiol + pCPA + bromocriptine = 29.35 ng/ml (23.01 - 48.74), p<0.05. Naloxone administration partially reduced estrogen-induced high prolactin concentrations, but did not affect prolactin secretion stimulation determined by pCPA. Overall, the data from this report confirm the involvement of the dopaminergic system and, to a lesser degree, of endogenous opioids in prolactin secretion stimulation determined by estradiol. Furthermore, our results suggest that the stimulatory action of pCPA on prolactin secretion in estradiol-treated OVX rats is mediated by serotonin, which may also act indirectly on dopamine neurons.

Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells.

We have shown previously that the VEGF system plays a crucial role in regulation of tumor angiogenesis during the development of estrogen-induced prolactin-secreting pituitary tumors in Fisher 344 rats. Studies also suggested that both endothelial and non-endothelial cells expressed VEGF. However, several questions concerning the VEGF signals in regulation of estrogen-induced angiogenesis in rat pituitary remained unanswered. VEGF exists in a number of isoforms in human and rodent tissue (i.e., VEGF206h/205r, VEGF189h/188r, VEGF165h/164r, VEGF145h/144r and VEGF121) that differ in their molecular masses and biological activities. The VEGF isoforms bind with two tyrosine-kinase receptors, KDR/flk-1 and flt-1. In addition, VEGF165 binds with a newly identified co-receptor, neuropilin-1, which is expressed in human endothelial cells and several types of non-endothelial cells including tumor cells. The present study was undertaken to elucidate which isoforms of VEGF are predominantly expressed in normal Fisher 344 rat pituitaries, estrogen-induced prolactin secreting rat pituitary tumors and in prolactin secreting rat pituitary tumor cell line (GH3 cell line). To identify the isoform, RT-PCR with primer pairs derived from exon 1 and exon 8 of the VEGF gene, cloning, sequencing and Western blot analysis were performed. The status of neuropilin-1 in the rat pituitaries (normal and transformed) and GH3 pituitary tumor cell line has also been investigated using RT-PCR and Western blot analysis. These studies demonstrate that normal rat pituitaries, estrogen-induced rat pituitary tumors and GH3 pituitary tumor cells expressed VEGF164 and co-receptor, neuropilin-1. The VEGF164 was the predominant form in all of these cells. The VEGF164 and neuropilin-1 mRNA and protein levels were significantly higher in the estrogen-induced pituitary tumors and GH3 tumor cell line, as compared to normal pituitary. The data suggest that both VEGF164 and neuropilin-1 may actively participate in modulation of tumor angiogenesis and the development of pituitary tumors in Fisher 344 rats.

Augmentation of Prolactin Release by α-Melanocyte Stimulating Hormone Is Possibly Mediated by Melanocortin 3-Receptors in the Mouse Anterior Pituitary Cells

Suckling- and estrogen-induced prolactin release from the anterior pituitary is mediated by alpha-melanocyte stimulating hormone (alpha-MSH) secreted by the intermediate lobe of the pituitary in the rat. Melanocortin 5-receptors are expressed in the anterior pituitary and probably mediate the alpha-MSH function. In contrast, the mouse anterior pituitary does not express the receptor. To examine whether or not alpha-MSH regulates prolactin release in mice, we performed cell immunoblot assay using anterior pituitary cells from adult female mice. We found that alpha-MSH acted on mammotrophs (prolactin-secreting cells) and stimulated prolactin release in a dose dependent manner. A series of RT-PCR using oligonucleotide primer pairs specific for each subtypes of melanocortin receptors revealed that the melanocortin 3-receptor is the sole receptor expressed in the mouse anterior pituitary. These results suggest that alpha-MSH-induced prolactin release is mediated by melanocortin 3-receptors in female mice.

Effect of lipopolysaccharide on tumor necrosis factor and prolactin release from rat anterior pituitary cells.

TNF-alpha plays a critical role in the cascade of neuroendocrine events during inflammation and septic shock. It also affects the release of pituitary hormones and acts as a growth factor in immune and nonimmune cells. The aim of the present study was to investigate the release of TNF-alpha from rat anterior pituitary cells and the effect of the steroid medium on its release. Cultured anterior pituitary cells from lactating rats spontaneously released TNF-alpha. The presence of lipopolysaccharide (LPS, 0.1 microg/mL) in the culture medium significantly increased TNF-alpha release and inhibited prolactin release. Chronic estrogenization of ovariectomized rats or the presence of 17 beta-estradiol in the culture medium also increased TNF-alpha release. LPS significantly stimulated TNF-alpha release in all groups and abrogated the estrogen-induced prolactin release. We also investigated the effect of TNF-alpha on prolactin release. The presence of TNF-alpha (50 ng/mL) in the culture medium inhibited prolactin release from anterior pituitary cells. These data show that anterior pituitary cells in culture release TNF-alpha and that this release is stimulated by estrogens. Our results also indicate that LPS inhibits prolactin release in an estrogenic environment, suggesting that TNF-alpha could affect pituitary hormone release during endotoxemia.

Progesterone inhibits the estrogen-induced prolactin gene expression in the rat pituitary

The present study examines the inhibitory action of progesterone (P) on prolactin (PRL) gene expression in the anterior pituitary of ovariectomized, estradiol (OVX + E) treated adult rats. A single injection of P (l mg) was administered s.c. to OVX + E treated rats, and animals were killed at 3, 6, 9, and 36 h following P administration. Northern blot analysis showed that P suppressed the E-enhanced PRL mRNA level at 3, 6, and 9 h, but not at 36 h following P administration. When the second injection of P (1 mg) was given at 30 h after the first P, it again suppressed the E-induced PRL mRNA level, indicating that the inhibitory effect of P may not last until 36 h. The inhibitory action of P was dose-dependent, and the pretreatment of RU486 (100 μg/rat), a P receptor antagonist at 1 h before P injection partially restored PRL mRNA level which was inhibited by P. These data indicate that P plays a crucial role in the regulation of PRL gene expression in the rat pituitary.

Central Administration of Bombesin Blocks the Estrogen-Induced Afternoon Prolactin Surge

The effect of central administration of bombesin (BB), a neuropeptide originally isolated from the skin of frogs, on the estrogen-induced afternoon prolactin (PRL) surge was studied. Two doses of BB, 0.15 and 0.75 micrograms/rat, were injected into the lateral cerebroventricle of estrogen-primed ovariectomized rats at 12.00 h through preimplanted cannulae. Serial blood samples were obtained through preimplanted intra-atrial catheters during the whole afternoon hours. The small dose of BB delayed the afternoon PRL surge for an hour, but did not prevent it from occurring. The large dose of BB, however, blocked the surge completely. When the same effective dose of BB was co-administered with a BB antagonist, [Leu13-psi(CH2NH) Leu14]-BB (L psi L-BB), it no longer inhibited the PRL surge. The afternoon PRL surge was also reinstated in BB-treated rats by giving a single injection of sulpiride (1 microgram/rat, i.v.), a dopamine antagonist, at 14.00 h in the same afternoon. These results suggest that BB, by acting through specific BB receptors, can inhibit the PRL surge possibly through activating the dopaminergic systems.

Effect of 5α-dihydrotestosterone and dexamethasone on estrogen receptors of the anterior pituitary and uterus

The administration of 5α-dihydrotestosterone (5α-DHT) and dexamethasone has been shown to attenuate estrogen-induced prolactin release in the estrogen-primed rat. Therefore, the effect of these compounds was studied on anterior pituitary and uterine estrogen receptors. Injection of 0.8 mg/kg body weight of 5α-DHT to ovariectomized adult rats treated with 2 μg estradiol/d for 4 days resulted in a significant decrease in occupied nuclear estrogen receptors of the anterior pituitary but not the uterus. Estrogen priming was essential for 5α-DHT effect on occupied nuclear anterior pituitary estrogen receptors because this effect did not occur in ovariectomized vehicle-treated control animals. The administration of 1 mg/kg body weight of dexamethasone brought about a decrease in uterine but not anterior pituitary nuclear estradiol receptors. These results provide further evidence that the regulation of estrogen receptor dynamics is different in the anterior pituitary and the uterus and that different steroids can exert tissue-specific effects.

Abolition of prolactin surge induced by ovarian steroid hormones in the lactating rat.

There are data indicating that stress-induced prolactin (PRL) release is blunted in the lactating rat like the release of other stress-associated hormones. In this experiment, the PRL release evoked by administration of estrogen, which is another principal stimulus for PRL release, was examined in ovariectomized lactating rats 8-15 days after delivery. Estradiol benzoate (EB, 20 micrograms) injections into ovariectomized nonlactating rats induced a PRL surge starting between 13:00 and 15:00 h with a peak at 17:00 h 2 days after the treatment, whereas the EB-induced PRL surge was absent in ovariectomized lactating rats separated from their pups at 09:00 h on the day or in mothers without separation from their pups. Injection of either thyrotropin-releasing hormone (TRH; 10 micrograms/kg) or pimozide (0.5 mg/kg) elevated serum PRL concentrations similarly in lactating and nonlactating rats when examined just before the beginning of the expected estrogen-induced PRL surge. Thus, the main cause for the reduced PRL response to estrogen in lactating rats seems not to be in the pituitary gland but in the brain. Progesterone, which is known to induce a PRL surge in ovariectomized estrogen-primed rats by acting on the mediobasal hypothalamus, also failed to evoke a PRL surge in lactating rats. Recovery from the inhibitory influence of suckling on PRL response to EB followed a time course similar to that observed in response to immobilization stress or to morphine injection; estrogen-induced PRL surge started to recover at 6 days and was almost fully recovered 8 days after weaning.(ABSTRACT TRUNCATED AT 250 WORDS)

Similarities and differences in progesterone and androgens in modulation of LH, FSH and PRL release: Unexpected properties of flutamide

The purpose of this study was to determine if the similarity of effect of progesterone and androgens on antagonism of estrogen-induced prolactin release also applied to the regulation of LH and FSH release. An additional objective was to examine the effect of the antiandrogen, flutamide, upon the ability of progesterone to induce gonadotropin secretion. Using the ovariectomized estrogen-primed immature rat, testosterone propionate suppressed LH and FSH secretion, whereas dihydrotestosterone only suppressed serum LH levels. In contrast, progesterone significantly elevated both serum LH and FSH levels. Thus, with respect to regulation of gonadotropin secretion, the effects of androgens and progesterone were dissimilar. In the estrogen-primed ovariectomized immature rat, flutamide was found to suppress LH, FSH and PRL secretion. Progesterone (0.8 mg/kg body wt) was incapable of overcoming this suppressive effect of flutamide. The effect of flutamide on gonadotropin secretion required estrogen priming. The effect of flutamide in suppressing LH, FSH and PRL release was not through suppression of an adrenal steroid as shown by adrenalectomy or the use of RU486. In the PMSG primed immature rat, flutamide had no effect on basal gonadotropin levels or ovulation. However, flutamide antagonized progesterone and triamcinolone acetonide-induced gonadotropin surges and blocked their ability to facilitate ovulation. These studies demonstrate that in the ovariectomized estrogen-primed immature rat flutamide has potent neuroendocrine regulatory ability leading to suppression of LH, FSH and PRL release. Flutamide also blocked progesterone and triamcinolone acetonide induced gonadotropin surges and ovulation in PMSG-primed immature female rats.

Dose‐Related Effects of Progesterone and 5 Alpha‐Dihydroprogesterone upon Estrogen‐Induced Prolactin Release

Abstract Previous work from our laboratory has shown that progesterone causes a rapid reduction of pituitary nuclear estrogen receptors. This effect is accompanied by a loss of estrogen action such as estrogen-induced progesterone receptor synthesis and prolactin release. Recent work has demonstrated that the effect of progesterone on estrogen receptor depletion is dose-related. Therefore the purpose of this study was to examine the effect of different doses of progesterone upon estrogen-induced prolactin release. Progesterone exhibited a multiphasic effect on estrogen-induced prolactin release. The 0.8 mg/kg body wt and 3.2 mg/kg body wt doses of progesterone significantly inhibited estrogen-induced prolactin release, whereas the intermediate dose, 2.0 mg/kg, was without effect. Progesterone is rapidly metabolized to 5alpha-dihydroprogesterone in the pituitary, and this metabolite has recently been shown to deplete pituitary estrogen receptors similar to progesterone. Thus the effect of 5alpha-dihydroprogesterone onstrogen-induced prolactin release was also examined. 5alpha-dihydroprogesterone was found to exhibit a multiphasic effect similar to progesterone in inhibiting estrogen-induced prolactin release. The 0.4 mg/kg and 2.0 mg/kg doses of 5alpha-dihydroprogesterone significantly inhibited estrogen-induced prolactin release, whereas the 0.8 mg/kg dose was ineffective. The effect of 5alpha-dihydroprogesterone required estrogen priming and was blocked by the antiprogestin, RU486, suggesting progesterone receptor mediation.

Paradoxical effects of oxytocin and vasopressin on basal prolactin secretion and the estrogen-induced prolatin surge

The roles of oxytocin (OT) and vasopressin (AVP) on both basal and estrogen-induced prolactin (PRL) secretion were examined. Adult female Sprague-Dawley rats that were ovariectomized for 3 weeks and received estrogen treatment for 1 week were used. Intravenous administration of hormones and serial blood sampling were accomplished through indwelling intraatrial catheters which were implanted two days before. Plasma PRL levels were measured by radioimmunoassay. Oxytocin at a dose of 20 μg/rat stimulated a moderate PRL release in the morning and lower doses (5 and 10 μg) were without effect. Vasopressin was most effective at a dose of 5 μg/rat in stimulating PRL release, while consecutive injections of higher doses (10 and 20 μg) were less effective. In contrast, TRH, ranging from 1 to 8 μg/rat, induced a dose-dependent increases in PRL secretion. Using the effective dosages determined from the morning studies, repeated injections of either OT, AVP or their specific antagonists MPOMeOVT ([1-(β-mercapto-β, β-cyclopentamethylene propanoic acid), 2-(0-methyl) tyrosine, 8-ornithine]-vasotocin) and d(CH 2) 5Tyr (me) AVP ([1-(β-mercapto-β, β-cyclo-pentamethylene propionic acid), 2-(0-methyl) tyrosine, 8-arginine]-vasopressin), were given hourly between 1300 to 1800h and blood samples were obtained hourly from 1100 to 1900h. It was found that either OT or AVP significantly reduced the afternoon PRL surge, while their antagonists were not as effective. When OT or AVP were administered together with their specific antagonists, the inhibitory effects of either hormone on PRL surge were reserved. Thus it is concluded that both OT and AVP assume a non-specific stress-like effect on PRL release, in which basal secretion is stimulated and surge secretion is inhibited.

Stress-Induced Suppression of the Prolactin Afternoon Surge in Ovariectomized, Estrogen-Treated Rats and the Nocturnal Surge in Pseudopregnant Rats Are Accompanied by an Increase in Median Eminence Dihydroxyphenylacetic Acid Concentrations

Experiments were performed to determine whether the suppression of prolactin (PRL) surges during restraint was accompanied by changes in the activity of tuberoinfundibular dopamine (TIDA) neurons in the median eminence. Animals were either ovariectomized and estrogen-treated (OVX-PEP) or cervically stimulated to induce pseudopregnancy (PSP). Restraint stress was administered by tying the hind legs together with plastic-coated bell wire. Animals were decapitated following 15 or 30 min of restraint stress or immediately after removal from the animal room (control) when PRL levels were basal (10.00 h), at the peak of the afternoon PRL surge in OVX-PEP animals (17.00 h) or the nocturnal PRL surge in PSP animals (05.00 h). Median eminence dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) were significantly decreased in control rats at 17.00 h when compared to control rats at 10.00 h (103.1 +/- 3.7 vs. 85.8 +/- 3.3 and 11.4 vs. 7.1 +/- 0.4 pg/micrograms protein, respectively) and plasma PRL was markedly elevated. Restraint stress at 10.00 h resulted in a significant increase in serum PRL, but this increase was not accompanied by a change in DA or DOPAC when compared to control animals (103.1 +/- 3.7 vs. 107.9 +/- 4.8 and 11.4 +/- 0.4 vs. 10.4 +/- 0.6 pg/micrograms protein, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland.

Estrogens are known to exert specific stimulatory effects on basal and dopamine-inhibited PRL secretion and synthesis as well as on PRL gene expression. However, dihydrotestosterone (DHT) and progesterone (P), although inactive alone, can reverse the effect of 17 beta-estradiol (E2) on PRL release both in vivo and in vitro. Using castrated male rats, we have studied the effect of E2 (0.25 micrograms), P (2 mg), or DHT (100 micrograms) administered twice daily for 14 days alone or in combination on pituitary PRL mRNA levels measured by quantitative in situ hybridization. Treatment with E2 increased the accumulation of PRL mRNA by about 2.6-fold. Administration of P or DHT alone failed to modify PRL mRNA concentrations. However, DHT could prevent by 80% the stimulatory effect of E2 on PRL mRNA levels. Similar results were obtained by dot blot hybridization assay. The effects of sex steroids on PRL mRNA were closely paralleled to pituitary PRL content measured by RIA. The present data demonstrate that the effect of sex steroids on immunodetectable PRL result from a modulation of PRL mRNA accumulation. The sexual dimorphism observed in pituitary PRL content results from a 3.5-fold greater accumulation of PRL mRNA in intact females than in male rats. These results also clearly show that quantitative in situ hybridization is a powerful tool in the investigation of the regulation of gene expression in addition to providing valuable information on the localization of specific mRNA.

Antagonism of estrogen-induced prolactin release by dihydrotestosterone.

Previous work from our laboratory has demonstrated that progesterone can inhibit estrogen-induced prolactin release in female rats. Since androgens have been reported to mimic progesterone actions in certain systems, and to antagonize estrogen action in rat uteri, the purpose of this study was to determine whether androgens, like progestins, can inhibit estrogen-induced prolactin release. The ovariectomized (26 days of age) immature rat was used as the model for analysis of this question. Dihydrotestosterone (DHT) was chosen to be used throughout the study since it does not undergo aromatization to estrogens. In response to estradiol exposure (2 micrograms/rat), prolactin release reached peak values at 12 h and returned to control levels by 24 h. A second injection of estradiol 13 h after its initial injection stimulated a second increase in serum prolactin at 25 h. A single injection of DHT (0.8 mg/kg BW) 1 h before the second estradiol injection blocked the increase in serum prolactin. DHT had no effect on basal serum prolactin levels. The DHT inhibition of estrogen-induced prolactin release required estrogen priming. A dose dependency for the DHT effect was demonstrated, with low doses effective and high doses ineffective, in inhibiting estrogen action. This effect of DHT seemed to be androgen receptor-mediated, since flutamide blocked the effect. However, the possibility of progestin receptor mediation could not be ruled out since RU486 also blocked DHT's effect. Flutamide was also effective in blocking progesterone's inhibition of estrogen-induced action. This is perhaps consistent with an overlap of activities in androgens and progestins reported by several investigators.(ABSTRACT TRUNCATED AT 250 WORDS)

Antagonism of Estrogen-Induced Prolactin Release by Progesterone1

Previous work from our laboratory has shown that during the process of nuclear occupancy of the progesterone receptor complex (1-2 h), nuclear estradiol receptors of the anterior pituitary are depleted. The purpose of this study was to determine whether the depletion of nuclear estradiol receptors by progesterone had functional biological significance. The ovariectomized (26 days of age) immature rat was used as the model for analysis of this question. The ability of estradiol to release prolactin from the anterior pituitary was the function chosen to determine the biological significance of the progesterone and estradiol interactions. In response to estradiol exposure (2 micrograms/rat), prolactin release reached peak values from 8 h to 12 h and returned to control levels by 24 h. A second injection of estradiol 13 h after the initial injection stimulated a second increase in serum prolactin at 25 h. This model of two injections of estradiol 13 h apart served to provide adequate levels of anterior pituitary progesterone receptors and elevated serum prolactin levels upon which superimposed progestin modulation could be examined. A single injection of progesterone (0.8 mg/kg BW) 1 h before the second estradiol injection blocked the increase in serum prolactin. This action was a receptor-mediated event because progesterone had no effect without estrogen priming or when the progesterone antagonist RU486 was used. Finally, when the interval between the progesterone and second estradiol injection was extended to 4 h, a time period when progesterone does not deplete pituitary nuclear estrogen receptors, the estrogen-induced increase in serum prolactin was not blocked.(ABSTRACT TRUNCATED AT 250 WORDS)

Rates of release of GABA and catecholamines in the mediobasal hypothalamus of ovariectomized and ovariectomized estrogen-treated rats: correlation with blood prolactin levels.

Push-pull cannulae were implanted into the mediobasal hypothalamus of ovariectomized (ovx) rats. After recovery animals were treated with estradiolbenzoate (E2B) or oil and they were perfused 3 days later. Only the E2B-treated animals which exhibited prolactin surges in the afternoon without concomitant LH surges were used in this study. In ovx animals hypothalamic GABA release, measured in 5-min intervals, was pulsatile, with pulses occurring every 37 min. This pattern was profoundly affected by E2B treatment: the pulse frequency was significantly reduced to 1 pulse every 117 min in steroid-treated rats. No differences in overall mean GABA release rates and pulse amplitudes were observed in ovx vs. E2B-treated rats. Our earlier demonstration of the existence of a large number of estrogen-receptive, GABAergic neurons in the MBH of rats is suggestive that these neurons change their secretory pattern in response to estrogen treatment. Estrogen-induced prolactin surges were accompanied by increased hypothalamic NE release. Concomitant changes in DA or E release rates were not demonstrable since catecholamine concentrations were too low to be reliable. However, the daily overall release rates of these two catecholamines were lower in E2B-treated rats compared to ovx animals. It is concluded that the positive feedback action of estradiol on prolactin release involves a stimulatory noradrenergic mechanism and may also involve estrogen-receptive, GABAergic neurons.(ABSTRACT TRUNCATED AT 250 WORDS)